ASCELIA

AN ONCOLOGY-DEDICATED DRUG DEVELOPMENT COMPANY

Magnus Corfitzen, CEO presenting at Redeye event in Malmö 12 Sep 2019

Download our Ascelia Pharma Fact sheet

Lead candidate Mangoral (phase III ready) is an MRI imaging drug being developed for detection and localization of liver metastases.

Oncoral (phase II ready) is a novel tablet-based irinotecan formulation, intended for treatment of advanced gastric (stomach) cancer.

• November 27 @ 08:00 - 17:00

  Vator Unicorn Summit, Stockholm

• December 1 - December 6

  RSNA 2019 (Radiology Society of North America)

• December 3 @ 13:00 - 14:00

  Investor Day – Västra Hamnen Corporate Finance

• 2019-11-14Bulletin from the Annual General Meeting in Ascelia Pharma AB on 14 November 2019
• 2019-11-08Q1 2019/2020 Financial Report: Preparations for Phase III study with Mangoral® on track
• 2019-10-25Change in Ascelia Pharma’s management team
• 2019-10-14Notice of Annual General Meeting of Ascelia Pharma AB
• 2019-10-14Ascelia Pharma publishes Annual Report for the financial year 2018/2019